10-Q: Adagio Medical Faces Going Concern Doubt Amid Zero Revenue

Adagio Medical Holdings, Inc. reported no revenue for Q2 2025 and expressed substantial doubt about its ability to continue as a going concern, despite receiving FDA Breakthrough Device designation.

Summary

• Reported no revenue for the three and six months ended June 30, 2025, a significant decrease from $0.254 million and $0.280 million in the prior year periods, respectively.
• Net loss improved to $3.9 million for Q2 2025 (from $5.7 million in Q2 2024) and $11.7 million for H1 2025 (from $13.0 million in H1 2024).
• Cash and cash equivalents decreased to $8.2 million as of June 30, 2025, from $20.6 million at December 31, 2024.
• Accumulated deficit grew to $82.2 million as of June 30, 2025, from $70.6 million at December 31, 2024.
• Net cash used in operating activities was $11.9 million for the six months ended June 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern, expecting current cash to fund operations only into Q4 2025.
• Implemented a corporate prioritization initiative in February 2025, focusing resources on the FULCRUM-VT clinical trial and new product design optimization, leading to one-time expenses and reduced payroll.
• Received FDA Breakthrough Device designation in April 2025 for its vCLAS Cryoablation System for drug-refractory, recurrent, sustained monomorphic ventricular tachycardia.
• The FULCRUM-VT U.S. IDE Pivotal Study is currently enrolling 206 patients across 20 centers in the U.S. and Canada, with completion anticipated in the second half of 2025.
• Remediated a material weakness in internal control over financial reporting as of May 15, 2025.

Sentiment

Score: 3

Explanation: While there's positive clinical progress with FDA Breakthrough Device designation and ongoing trials, the severe liquidity issues, zero revenue, and explicit 'going concern' warning overshadow these developments, indicating a high-risk financial situation.

Positives

• Received FDA Breakthrough Device designation in April 2025 for the vCLAS Cryoablation System, potentially accelerating development and review.
• Net loss decreased to $3.9 million for the three months ended June 30, 2025, from $5.7 million in the prior year period.
• Net loss decreased to $11.7 million for the six months ended June 30, 2025, from $13.0 million in the prior year period.
• Successfully remediated a material weakness in internal control over financial reporting as of May 15, 2025.
• Interest income significantly increased to $0.102 million for Q2 2025 (from $0.002 million in Q2 2024) and $0.266 million for H1 2025 (from $0.003 million in H1 2024) due to higher cash balances in an asset management account.

Negatives

• Reported nil revenue for the three and six months ended June 30, 2025, a 100% decrease from the prior year periods, primarily due to a pause in European commercial activity and inventory buyback.
• Substantial doubt exists about the company's ability to continue as a going concern, with current cash expected to fund operations only into Q4 2025.
• Cash and cash equivalents significantly decreased by $12.4 million to $8.2 million as of June 30, 2025, from $20.6 million at December 31, 2024.
• Accumulated deficit increased to $82.2 million as of June 30, 2025, from $70.6 million at December 31, 2024.
• Incurred a warrant liabilities fair value adjustment loss of $0.141 million for Q2 2025 and $0.103 million for H1 2025, compared to gains in prior year periods.
• Goodwill and Intangible Assets experienced significant impairment charges of $30.3 million and $18.9 million, respectively, in Q4 2024, driven by a sustained decline in share price and market capitalization.

Risks

• Substantial doubt about the ability to continue as a going concern due to limited revenue, recurring operating losses, and negative cash flows, with current cash expected to fund operations only into Q4 2025.
• Reliance on additional capital through public or private equity offerings, license agreements, debt financings, restructurings, collaborations, strategic alliances, and marketing or distribution arrangements, which may not be available on acceptable terms.
• Potential delays, limitations, reductions, or termination of product discovery and development activities or future commercialization efforts if unable to maintain sufficient financial resources.
• The corporate prioritization initiative implemented in February 2025 may result in unintended consequences such as loss of institutional knowledge, attrition beyond intended numbers, decreased employee morale, and difficulty pursuing new opportunities.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business, global supply chain, increase costs, and reduce profitability, with limited ability to pass increased costs to customers due to fixed pricing and reimbursement systems.
• Breakthrough Device designation by the FDA for vCLAS may not lead to a faster development, regulatory review, or approval process, nor does it increase the likelihood of ultimate PMA approval.
• The company operates in a very competitive and rapidly changing environment, with new risks and uncertainties emerging that could impact forward-looking statements.

Future Outlook

The company anticipates completing its FULCRUM-VT IDE pivotal clinical trial in the second half of 2025, with results to be submitted for U.S. FDA approval of its vCLAS Cryoablation System. Management expects research and development expenditures to increase in future periods to support growth strategies and new product development. Selling, general, and administrative expenses are projected to decrease slightly for the full year 2025 compared to 2024 due to the corporate prioritization initiative, but are expected to increase in subsequent periods as operations expand. The company is evaluating the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) and the recently enacted One Big Beautiful Bill Act (OBBBA) on its financial statements.

Management Comments

• Management intends to mitigate the conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern entity by (i) negotiating other cash equity or debt financing in the short-term, (ii) continuing to pursue the necessary regulatory approvals to launch commercially in the U.S. market, and (iii) executing cost-cutting measures to manage cash burn.
• We expect our selling, general and administrative expenses to decrease slightly for the full year 2025 compared to the full year 2024. This anticipated decrease is primarily due to lower payroll and personnel expenses resulting from the corporate prioritization initiative implemented on February 28, 2025, as well as the absence of transaction-related costs incurred in connection with the Business Combination completed in 2024. In future periods we expect our selling, general and administrative expenses to increase as we continue to expand on our operations and grow our business.

Industry Context

The company operates in the highly competitive and rapidly changing medical device industry, specifically focusing on ablation technologies for cardiac arrhythmias. Its vCLAS Cryoablation System for ventricular tachycardia (VT) aims to address an underserved patient population, differentiating itself from existing radiofrequency (RF) ablation catheters primarily designed for atrial fibrillation. The FDA Breakthrough Device designation for vCLAS highlights the potential for significant clinical benefit over current standards of care, positioning the company to potentially capture market share if regulatory approvals and commercialization are successful. However, the industry is dominated by large, well-capitalized companies, and success hinges on demonstrating superior safety and effectiveness, securing regulatory approvals, expanding sales, and obtaining adequate reimbursement, all while managing substantial capital requirements.

Comparison to Industry Standards

• The company's vCLAS Cryoablation System is purpose-built for Ventricular Tachycardia (VT), aiming to address limitations of existing Radio Frequency (RF) ablation catheters primarily designed for Atrial Fibrillation (AF). This suggests a differentiated approach compared to competitors who may be adapting AF-focused devices for VT.
• Preliminary data from the CRYOCURE-VT trial showed a 0% rate of major adverse events, 94% acute procedural success, 60% freedom from sustained VT, and 81% freedom from ICD shock at six months. These results are presented as favorable compared to the current standard of care, including RF energy ablations, but specific comparative data for other companies or devices are not provided in the filing.
• The FDA Breakthrough Device designation for vCLAS indicates that the FDA believes the device has the potential to provide more effective treatment for a life-threatening condition compared to existing approved alternatives, which is a positive external validation of its potential.
• The company's financial position, characterized by recurring operating losses, negative cash flows, and substantial doubt about its going concern ability, contrasts sharply with established, profitable medical device companies. Its reliance on external financing for clinical development and future commercialization is typical for a development-stage medical technology company but indicates a higher risk profile compared to industry leaders.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently party to any material legal proceedings.

Related Party Transactions

• Incurred $0.2 million (Q2 2025) and $0.4 million (H1 2025) for finance, accounting, and general and administrative support services under a Shared Services Agreement with Fjord Ventures, a company owned and operated by the company's former Chief Executive Officer.
• Legacy Adagio issued a $0.5 million convertible promissory note to Fjordinvest, LLC, a company owned and operated by the Legacy Adagio's Chief Executive Officer, Olav Bergheim, on October 27, 2022.
• Issued a $7.0 million Convertible Securities Note to Perceptive PIPE Investor, the controlling party of the company, in exchange for their investment in Legacy Adagio's February 2024 Convertible Notes.
• Issued 4,372,607 common shares and 3,540,000 Base Warrants to Perceptive PIPE Investor, the controlling party, to settle outstanding principal and accrued interest of Bridge Financing Notes.
• Issued 2,250,352 common shares and 1,905,069 Base Warrants to Perceptive PIPE Investor, the controlling party, for an additional cash investment of approximately $15.9 million.

Next Steps

• Complete enrollment and anticipate completion of the FULCRUM-VT U.S. IDE pivotal clinical trial in the second half of 2025.
• Submit results of the FULCRUM-VT trial to support U.S. Food and Drug Administration (FDA) approval of the vCLAS Cryoablation System.
• Negotiate other cash equity or debt financing in the short-term to address liquidity concerns.
• Continue to pursue necessary regulatory approvals to launch commercially in the U.S. market.
• Execute cost-cutting measures to manage cash burn.
• Assess the effect of ASU 2023-09 (Income Taxes) on financial statement disclosures, effective for annual periods beginning December 31, 2025.
• Evaluate the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses), effective for fiscal years beginning after December 15, 2026.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) enacted July 4, 2025, on consolidated financial statements.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt about its ability to continue as a going concern' and projecting cash to last only into Q4 2025. The complete absence of revenue for the quarter and first half of 2025, coupled with a growing accumulated deficit and significant cash burn from operations, indicates an unsustainable financial trajectory. While the FDA Breakthrough Device designation and ongoing clinical trials are positive for product development, the immediate and critical liquidity issues present an overwhelming risk. The need for significant additional capital in the short term, with no assurance of availability on acceptable terms, makes the stock a high-risk investment with a strong likelihood of further dilution or financial restructuring that would negatively impact current shareholders.

Keywords

Adagio Medical Holdings, ADGM, SEC Filing, 10-Q, Quarterly Report, Medical Technology, Cardiac Arrhythmias, Ventricular Tachycardia, Cryoablation, vCLAS System, FDA Breakthrough Device, FULCRUM-VT Trial, Going Concern, Financial Results, Net Loss, Revenue, Cash Flow, Capital Raise, Biotechnology, Medical Devices, Clinical Trials, Corporate Prioritization